Nina Ivers - Xbrane Biopharma Head HR
| XBRANE Stock | SEK 0.21 0.01 4.55% |
Insider
Nina Ivers is Head HR of Xbrane Biopharma AB
| Age | 53 |
| Phone | 46 7 60 34 67 33 |
| Web | https://www.xbrane.com |
Xbrane Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tobias Antius | Novotek AB | 51 | |
| Lena Andersson | Precio Fishbone AB | N/A | |
| Emelie Gozzi | C Rad AB | N/A | |
| Xiaodong Wang | C Rad AB | 44 | |
| Bjorn Bemgard | Precio Fishbone AB | N/A | |
| Priscilla Kazumba | C Rad AB | N/A | |
| Per Ljungberg | Precio Fishbone AB | N/A | |
| Christer Johansson | Precio Fishbone AB | 59 | |
| Hakan Axelsson | C Rad AB | 55 | |
| Ivan Astralaga | C Rad AB | N/A | |
| Helena Bramstorp | Novotek AB | 41 | |
| Antti MP | Novotek AB | 45 | |
| Jesper Alfonsson | Precio Fishbone AB | N/A | |
| Lars Levin | C Rad AB | 52 | |
| Veronika Grozdanovska | Novotek AB | 53 | |
| Tim Thurn | C Rad AB | 42 | |
Management Performance
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 |
Xbrane Biopharma Leadership Team
Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Edman, Director | ||
| Nina Ivers, Head HR | ||
| Maria Edebrink, Head Assurance | ||
| Martin mark, Chief Officer | ||
| David Vikstrm, Chief Officer | ||
| Paolo Sarmientos, Head of Controlled Release Generics | ||
| Associate Gier, CoFounder | ||
| Martin Amark, CEO | ||
| Maris Hartmanis, Director | ||
| David Vikstrom, CTO | ||
| Carlo Colombo, Head of Production Controlled Release Generics | ||
| Anders Tullgren, Chairman of the Board | ||
| Ivan CohenTangui, Director | ||
| Saeid Esmaeilzadeh, Chairman of the Board | ||
| Siavash Bashiri, COO, Head of Biosimilars | ||
| Dina Jurman, Head of Clinical Affairs | ||
| Eva Nilsagard, Director | ||
| Anette Lindqvist, CFO Relations | ||
| Susanna Helgesen, CFO, Head of Investor Relations | ||
| Karin Wingstrand, Director | ||
| Alessandro Sidoli, Director | ||
| Giorgio Chirivi, Director | ||
| Samuel Wagner, CoFounder Board | ||
| Erik Domines, G Counsel |
Xbrane Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xbrane Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Xbrane Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Xbrane Biopharma's short interest history, or implied volatility extrapolated from Xbrane Biopharma options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xbrane Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |